Cyclo Therapeutics, Inc. is a clinical stage biotechnology company. The Company develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease. The Company’s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. NPC is a fatal cholesterol metabolism disease that impacts the...